Liquid biopsy company Angle said a key product had been been successfully used to improve the workflows and sensitivity of lymph node analysis in melanoma.
The related research, led by Dr Bernhard Polzer at the Fraunhofer Institute for Toxicology and Experimental Medicine, was published in the International Journal of Cancer.
'This is another example of our leveraged approach with research customers delivering new applications for Parsortix,' chief executive Andrew Newland said.
'There is now the potential for the Parsortix system to be adopted as a standard approach for analysing lymph nodes, which is a requirement for all patients diagnosed with melanoma and several other cancer types.'
At 1:37pm: (LON:AGL) Angle PLC share price was +2.5p at 57.5p